Financial giants have made a conspicuous bullish move on Gilead Sciences. Our analysis of options history for Gilead Sciences (NASDAQ:GILD) revealed 9 unusual trades.
Delving into the details, we found 55% of traders were bullish, while 44% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $72,059, and 7 were calls, valued at $273,450.
Expected Price Movements
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $60.0 to $70.0 for Gilead Sciences during the past quarter.
Insights into Volume & Open Interest
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Gilead Sciences's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Gilead Sciences's significant trades, within a strike price range of $60.0 to $70.0, over the past month.
Gilead Sciences Call and Put Volume: 30-Day Overview
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GILD | CALL | SWEEP | BULLISH | 01/17/25 | $4.35 | $4.25 | $4.35 | $67.50 | $93.5K | 534 | 0 |
| GILD | PUT | SWEEP | BEARISH | 11/15/24 | $3.7 | $3.65 | $3.7 | $65.00 | $37.0K | 1.3K | 200 |
| GILD | PUT | SWEEP | BULLISH | 11/15/24 | $3.75 | $3.65 | $3.65 | $65.00 | $35.0K | 1.3K | 305 |
| GILD | CALL | SWEEP | BULLISH | 01/17/25 | $5.3 | $5.2 | $5.3 | $65.00 | $33.9K | 2.0K | 50 |
| GILD | CALL | SWEEP | BULLISH | 05/17/24 | $6.2 | $6.0 | $6.18 | $60.00 | $30.9K | 89 | 50 |
About Gilead Sciences
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
After a thorough review of the options trading surrounding Gilead Sciences, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Gilead Sciences's Current Market Status
- Currently trading with a volume of 5,292,112, the GILD's price is up by 2.29%, now at $66.06.
- RSI readings suggest the stock is currently is currently neutral between overbought and oversold.
- Anticipated earnings release is in 83 days.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.